Dapagliflozin as an Adjunct to Insulin Improves Time-in-Range and Glycemic Variability versus Acarbose in Adults With Type 1 Diabetes: A Randomized Crossover Trial
Dapagliflozin as an Adjunct to Insulin Improves Time-in-Range and Glycemic Variability versus Acarbose in Adults With Type 1 Diabetes: A Randomized Crossover Trial. // Endocrine Practice. – URL: https://www.sciencedirect.com/science/article/pii/S1530891X26010220?dgcid=rss_sd_all
Dapagliflozin as an Adjunct to Insulin Improves Time-in-Range and Glycemic Variability versus Acarbose in Adults With Type 1 Diabetes: A Randomized Crossover Trial. Endocrine Practice. https://www.sciencedirect.com/science/article/pii/S1530891X26010220?dgcid=rss_sd_all
“Dapagliflozin as an Adjunct to Insulin Improves Time-in-Range and Glycemic Variability versus Acarbose in Adults With Type 1 Diabetes: A Randomized Crossover Trial.” Endocrine Practice.
@article{article44439,
title = {Dapagliflozin as an Adjunct to Insulin Improves Time-in-Range and Glycemic Variability versus Acarbose in Adults With Type 1 Diabetes: A Randomized Crossover Trial},
journal = {Endocrine Practice},
url = {https://www.sciencedirect.com/science/article/pii/S1530891X26010220?dgcid=rss_sd_all}
}